Drug Profile
Sitravatinib - Mirati Therapeutics
Alternative Names: IND-155305; MG-516; MG91516; MGCD-0516; MGCD-516; Sitravatinib-malate; Sitravatinib-malate-Mirati-TherapeuticsLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator MethylGene
- Developer BeiGene; Cancer Research UK; Columbia University; Fudan University; Mirati Therapeutics; University Health Network; University of Birmingham
- Class Amides; Amines; Antineoplastics; Cyclopropanes; Ethers; Fluorobenzenes; Pyridines; Small molecules; Thienopyridines
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Eph family receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-mer inhibitors; Proto-oncogene protein c-met inhibitors; Receptor protein-tyrosine kinase antagonists; RON protein inhibitors; TIE 2 receptor antagonists; Tropomyosin-related kinase antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
- Phase II/III Solid tumours
- Phase II Cholangiocarcinoma; Liposarcoma; Oesophageal cancer; Soft tissue sarcoma; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer; Uveal melanoma
- Phase I/II Gastric cancer; Liver cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Renal-cell-carcinoma(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (PO)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Australia (PO)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (PO)